Interaction of Autotaxin With Lipoprotein(a) in Patients With Calcific Aortic Valve Stenosis

Overview

Journal JACC Basic Transl Sci

Date 2020 Oct 5

PMID 33015412

Citations 14

Authors

Raphaelle Bourgeois

Romain Devillers

Nicolas Perrot

Audrey-Anne Despres

Marie-Chloe Boulanger

Patricia L Mitchell

Jakie Guertin

Patrick Couture

Michael B Boffa

Corey A Scipione

Philippe Pibarot

Marlys L Koschinsky

Patrick Mathieu

Benoit J Arsenault

Affiliations

Soon will be listed here.

Abstract

Our objectives were to determine whether autotaxin (ATX) is transported by lipoprotein(a) [Lp(a)] in human plasma and if could be used as a biomarker of calcific aortic valve stenosis (CAVS). We first found that ATX activity was higher in Lp(a) compared to low-density lipoprotein fractions in isolated fractions of 10 healthy participants. We developed a specific assay to measure ATX-Lp(a) in 88 patients with CAVS and 144 controls without CAVS. In a multivariable model corrected for CAVS risk factors, ATX-Lp(a) was associated with CAVS (p = 0.003). We concluded that ATX is preferentially transported by Lp(a) and might represent a novel biomarker for CAVS.

Citing Articles

Reduced Oxidative Susceptibility of Lp(a) and LDL Fractions as a Pleiotropic Effect of Lipoprotein Apheresis in Patients with Elevated Lp(a) and ASCVDs.

Krzesinska A, Marlega-Linert J, Chyla-Danil G, Marcinkowska M, Rogowska P, Stumska K Int J Mol Sci. 2025; 25(24.

PMID: 39769362 PMC: 11676408. DOI: 10.3390/ijms252413597.

Role of Lipoprotein (A) in aortic valve stenosis: Novel disease mechanisms and emerging pharmacotherapeutic approaches.

Khan M, Zahir R, Dominguez A, Romeo F Int J Cardiol Heart Vasc. 2024; 55:101543.

PMID: 39555492 PMC: 11564994. DOI: 10.1016/j.ijcha.2024.101543.

Impact of Social Determinants of Health and Lifestyle on Association Between Lipoprotein(a) and Cardiovascular Events.

Brandt E, Kirch M, Patel N, Chennareddy C, Murthy V, Goonewardena S JACC Adv. 2024; 3(7):101016.

PMID: 39129977 PMC: 11313040. DOI: 10.1016/j.jacadv.2024.101016.

Amyloid and collagen templates in aortic valve calcification.

Jayaraman S, Narula N, Narula J, Gursky O Trends Mol Med. 2024; 30(11):1010-1019.

PMID: 38845326 PMC: 11563925. DOI: 10.1016/j.molmed.2024.04.015.

Diacylglycerols and Lysophosphatidic Acid, Enriched on Lipoprotein(a), Contribute to Monocyte Inflammation.

Dzobo K, Cupido A, Mol B, Stiekema L, Versloot M, Winkelmeijer M Arterioscler Thromb Vasc Biol. 2024; 44(3):720-740.

PMID: 38269588 PMC: 10880937. DOI: 10.1161/ATVBAHA.123.319937.

References

Capoulade R, Chan K, Yeang C, Mathieu P, Bosse Y, Dumesnil J . Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis. J Am Coll Cardiol. 2015; 66(11):1236-1246. DOI: 10.1016/j.jacc.2015.07.020. View

Tsimikas S . A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. J Am Coll Cardiol. 2017; 69(6):692-711. DOI: 10.1016/j.jacc.2016.11.042. View

Stewart B, Siscovick D, Lind B, Gardin J, Gottdiener J, Smith V . Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol. 1997; 29(3):630-4. DOI: 10.1016/s0735-1097(96)00563-3. View

Glader C, Birgander L, Soderberg S, Ildgruben H, Saikku P, Waldenstrom A . Lipoprotein(a), Chlamydia pneumoniae, leptin and tissue plasminogen activator as risk markers for valvular aortic stenosis. Eur Heart J. 2003; 24(2):198-208. DOI: 10.1016/s0195-668x(02)00385-8. View

Choi J, Zhang W, Gu X, Chen X, Hong L, Laird J . Lysophosphatidylcholine is generated by spontaneous deacylation of oxidized phospholipids. Chem Res Toxicol. 2010; 24(1):111-8. PMC: 3021597. DOI: 10.1021/tx100305b. View

Shen M, Tastet L, Bergler-Klein J, Pibarot P, Clavel M . Blood, tissue and imaging biomarkers in calcific aortic valve stenosis: past, present and future. Curr Opin Cardiol. 2017; 33(2):125-133. DOI: 10.1097/HCO.0000000000000487. View

Nsaibia M, Mahmut A, Boulanger M, Arsenault B, Bouchareb R, Simard S . Autotaxin interacts with lipoprotein(a) and oxidized phospholipids in predicting the risk of calcific aortic valve stenosis in patients with coronary artery disease. J Intern Med. 2016; 280(5):509-517. DOI: 10.1111/joim.12519. View

Lindman B, Clavel M, Mathieu P, Iung B, Lancellotti P, Otto C . Calcific aortic stenosis. Nat Rev Dis Primers. 2016; 2():16006. PMC: 5127286. DOI: 10.1038/nrdp.2016.6. View

Mathieu P, Boulanger M . Basic mechanisms of calcific aortic valve disease. Can J Cardiol. 2014; 30(9):982-93. DOI: 10.1016/j.cjca.2014.03.029. View

10.

Aoki J, Inoue A, Okudaira S . Two pathways for lysophosphatidic acid production. Biochim Biophys Acta. 2008; 1781(9):513-8. DOI: 10.1016/j.bbalip.2008.06.005. View

11.

Arsenault B, Boekholdt S, Dube M, Rheaume E, Wareham N, Khaw K . Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective Mendelian randomization study and replication in a case-control cohort. Circ Cardiovasc Genet. 2014; 7(3):304-10. DOI: 10.1161/CIRCGENETICS.113.000400. View

12.

Kamstrup P, Tybjaerg-Hansen A, Nordestgaard B . Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol. 2013; 63(5):470-7. DOI: 10.1016/j.jacc.2013.09.038. View

13.

Zheng K, Tsimikas S, Pawade T, Kroon J, Jenkins W, Doris M . Lipoprotein(a) and Oxidized Phospholipids Promote Valve Calcification in Patients With Aortic Stenosis. J Am Coll Cardiol. 2019; 73(17):2150-2162. PMC: 6494952. DOI: 10.1016/j.jacc.2019.01.070. View

14.

Thanassoulis G, Campbell C, Owens D, Smith J, Smith A, Peloso G . Genetic associations with valvular calcification and aortic stenosis. N Engl J Med. 2013; 368(6):503-12. PMC: 3766627. DOI: 10.1056/NEJMoa1109034. View

15.

Koschinsky M, Tomlinson J, Zioncheck T, Schwartz K, Eaton D, Lawn R . Apolipoprotein(a): expression and characterization of a recombinant form of the protein in mammalian cells. Biochemistry. 1991; 30(20):5044-51. DOI: 10.1021/bi00234a029. View

16.

Schober A, Siess W . Lysophosphatidic acid in atherosclerotic diseases. Br J Pharmacol. 2012; 167(3):465-82. PMC: 3449253. DOI: 10.1111/j.1476-5381.2012.02021.x. View

17.

Mathieu P, Arsenault B, Boulanger M, Bosse Y, Koschinsky M . Pathobiology of Lp(a) in calcific aortic valve disease. Expert Rev Cardiovasc Ther. 2017; 15(10):797-807. DOI: 10.1080/14779072.2017.1367286. View

18.

Nsaibia M, Boulanger M, Bouchareb R, Mkannez G, Le Quang K, Hadji F . OxLDL-derived lysophosphatidic acid promotes the progression of aortic valve stenosis through a LPAR1-RhoA-NF-κB pathway. Cardiovasc Res. 2017; 113(11):1351-1363. PMC: 5852522. DOI: 10.1093/cvr/cvx089. View

19.

Siess W, Zangl K, Essler M, Bauer M, Brandl R, Corrinth C . Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions. Proc Natl Acad Sci U S A. 1999; 96(12):6931-6. PMC: 22019. DOI: 10.1073/pnas.96.12.6931. View

20.

Garcia D, Pibarot P, Dumesnil J, Sakr F, Durand L . Assessment of aortic valve stenosis severity: A new index based on the energy loss concept. Circulation. 2000; 101(7):765-71. DOI: 10.1161/01.cir.101.7.765. View